Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Psyence Group Inc PSYGF


Primary Symbol: C.PSYG

Psyence Group Inc. is a Canada-based life science biotechnology company with a focus on natural psychedelics. The Company is focused on the research, cultivation and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and in support of mental wellness. It cultivates natural psilocybin mushrooms (Psilocybe Cubensis) at its... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (CSE:PSYG)

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

GlobeNewswire October 31, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

GlobeNewswire October 25, 2024

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

GlobeNewswire October 14, 2024

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

GlobeNewswire September 20, 2024

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

GlobeNewswire September 19, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

GlobeNewswire September 18, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

GlobeNewswire September 16, 2024

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

GlobeNewswire July 26, 2024

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

GlobeNewswire April 16, 2024

Bullboard Posts (CSE:PSYG)

RE:RE:What is the status of this C>PSYG ????

Contrarian delight?
panapple42 - July 13, 2024

RE:What is the status of this C>PSYG ????

Glad I stayed away from this symbol. Why is this even listed here? https://finance.yahoo.com/news/psyence-biomedical-ltd-receives...
panapple42 - July 13, 2024

What is the status of this C>PSYG ????

https://stockhouse.com/news/press-releases/2024/01/25/psyence-biomedical-ltd-approved-to-list-on-nasdaq-following-completion-of Are we...
panapple42 - February 17, 2024

RE:Competing with illegal stores

is this thing still alive?
panapple42 - December 13, 2023

Competing with illegal stores

How can these folks compete when there's an illegal shroom shop on every corner in Vancouver, Toronto, Los Angeles and Boston? 
kirktop - May 19, 2023

RE:Psychedelic Retreats vs Psilocybin Microdosing Retreats🤓

Definitely looking into this stock thanks alot for this tip !!!!!! I'm always on the research side of things on weekends because the...
AshleySiobaun - September 10, 2022